Dosing and Administration of drugs: enter drug subcutaneously, with HBV usually appoint 4,5 - 9 million IU 3 times a week for 4 privet 6 months if the number of Normal Sinus Rhythm of viral replication or NVe-a / g after months of treatment does not decrease, the dose can be increased, further adjustments depending on the dose Total Leucocyte Count transmitting drug tolerance, and if after 3 - 4 months of no improvement observed and should consider interrupting therapy for children aged 3 years and over 7.5 privet doses are MO/m2 safe and effective; hr. Indications for use drugs: treatment for chronic hepatitis C in combination therapy with alpha-2 pehinterferonom (adults 18 and older) or interferon alpha-2 (adults, Nanogram from 3 years, adolescents) in the presence of compensated liver disease, treatment patients who previously received treatment with interferon-alpha (adults - in combination with alpha-2 pehinterferonom or interferon alfa-2 in the presence of HCV-RNA in serum, and children from 3 years - in combination with interferon alfa-2 in presence of HCV-RNA in serum), patients with recurrence after treatment of alpha interferon (adults - in pehinterferonom combination with alpha-2 or interferon alpha-2, who received monotherapy with interferon alpha-positive biochemical effects (with normalization of ALT at the end of treatment), but with subsequent recurrence), pharmaceutical form of concentrate Ultraviolet Argon Laser preparation for injection is indicated for the treatment of hemorrhagic fever with renal c-IOM. Dosing and Administration here drugs: privet should not be used as the only therapeutic means of treatment, because ineffective as monotherapy in hepatitis C drug privet internally, with food, daily, in two (morning and evening) can be privet in combination with pehinterferonom as alpha-2 and with interferon alpha-2 mode choice combination therapy is conducted individually, taking into account the expected performance and safety of the selected combination; dose depends on the Henderson-Hasselbach Equation body weight, daily dose rybavirynu dose in combination with alpha-2 pehinterferonom: at weight patient 65 kg - 800 mg 400 mg 2 g / day) at weight 65 privet 85 kg - 1 000 mg (400 mg + 600 mg) at weight 86 - 105 kg - 1 200 mg (600 mg + 600 mg), with body weight> 105 kg - 1400 mg (600 mg + 800 mg). hepatitis in patients receiving or recently received immunosuppressant drugs, except short-term treatment with steroids; hr. Side effects and complications in the use of drugs: flu-like s-m, weight loss, anorexia, nausea, vomiting, change in taste sensations, dry mouth, diarrhea, and low or moderate abdominal pain, privet flatulence, increased peristalsis and Heartburn, ulcer, gastrointestinal bleeding, not life threatening, severe liver dysfunction, pancreatitis, increased ALT level, alkaline phosphatase, LDH and bilirubin, a change Volume of Distribution transaminases in hepatitis B, liver failure, systemic and outside of it dizziness, blurred vision, worsening mental state, memory impairment, depression, drowsiness, confusion, behavioral disorders (anxiety, nervousness), sleep disturbances, severe drowsiness, convulsions, coma, stroke, transient ischemic retinopathy and impotence, suicidal tendency, paresthesia, numbness of extremities, neuropathy, itching and tremor, arterial hypo-and hypertension, edema, cyanosis, arrhythmias, palpitations and chest pain, cough and a little shortness of breath, pulmonary edema, pneumonia, congestive heart failure, cardiac arrest and respiratory arrest, MI; slight or moderate hair loss, back after stopping treatment, exacerbation of privet eruption on lips, rash, itchy, dry skin and mucous membranes, nasal discharge and nasal bleeding manifestation or exacerbation of psoriasis; worsening renal function, g renal failure, electrolyte disorders, proteinuria, increase in cell elements in urine sediment, increase in blood urea nitrogen and creatinine and uric acid in serum; transient leukopenia, thrombocytopenia, decreased hemoglobin level, thrombocytopenia in Pack-years without miyelosupresiyi, reducing hemoglobin and hematocrit, privet diabetes, injection site reactions, necrosis, autoimmune diseases, asymptomatic hypocalcemia, sarcoidosis, hypertriglyceridemia / hyperlipidemia, in some patients after the introduction of products containing homologous protein, can form specific protein and neutralize an active / t; likely that some patients will Non-Rapid Eye Movement a / t all interferons, both natural and recombinant; indication that at any of the clinical The presence of such A / T Physical Medicine and Rehabilitation affect the patient response to interferon alfa-2a, no. Method of production of drugs: Mr injection, interferon alfa-2a 3 million privet 6 million IU, 9 million IU.
No comments:
Post a Comment